Raymond James analyst, Elliot Wilbur, reiterated an Outperform rating on Adamis Pharmaceuticals (NASDAQ: ADMP) as the company continues to make ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE